<div><h3>Background</h3><p>We describe molecular processes that can facilitate pathogenesis of Alzheimer's disease (AD) by analyzing the catalytic cycle of a membrane-imbedded protease γ-secretase, from the initial interaction with its C99 substrate to the final release of toxic Aβ peptides.</p> <h3>Results</h3><p>The C-terminal AICD fragment is cleaved first in a pre-steady-state burst. The lowest Aβ42/Aβ40 ratio is observed in pre-steady-state when Aβ40 is the dominant product. Aβ42 is produced after Aβ40, and therefore Aβ42 is not a precursor for Aβ40. The longer more hydrophobic Aβ products gradually accumulate with multiple catalytic turnovers as a result of interrupted catalytic cycles. Saturation of γ-secretase with its C99 substrate...
Alzheimer Disease (AD) is the most common neurodegenerative disorder in the world. One of the neurop...
γ-secretase is involved in the final processing of the amyloid precursor protein into a heterogeneou...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
BACKGROUND: We describe molecular processes that can facilitate pathogenesis of Alzheimer's disease ...
Pathogenic changes in γ-secretase activity, along with its response to different drugs, can be affec...
The production and aggregation of the amyloid β-peptide (Aβ) is thought to play a central role in Al...
<div><h3>Background</h3><p>Selective modulation of different Aβ products of an intramembrane proteas...
The processing of the amyloid-β protein precursor (AβPP) by β- and γ-secretases is a pivotal event i...
The membrane-embedded γ-secretase complex carries out hydrolysis within the lipid bilayer in proteol...
γ-secretase is responsible for the proteolysis of amyloid precursor protein (APP) into short, aggreg...
Background: Aβ peptides are generated by stepwise cleavage of the amyloid precursor protein. Results...
BACE1 (β-secretase) and α-secretase cleave the Alzheimer's amyloid β protein (Aβ) precursor (APP) to...
ABSTRACT: γ-Secretase catalyzes the final cleavage of the amyloid precursor protein (APP), resulting...
SummaryDevelopment of disease-modifying therapeutics is urgently needed for treating Alzheimer disea...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
Alzheimer Disease (AD) is the most common neurodegenerative disorder in the world. One of the neurop...
γ-secretase is involved in the final processing of the amyloid precursor protein into a heterogeneou...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
BACKGROUND: We describe molecular processes that can facilitate pathogenesis of Alzheimer's disease ...
Pathogenic changes in γ-secretase activity, along with its response to different drugs, can be affec...
The production and aggregation of the amyloid β-peptide (Aβ) is thought to play a central role in Al...
<div><h3>Background</h3><p>Selective modulation of different Aβ products of an intramembrane proteas...
The processing of the amyloid-β protein precursor (AβPP) by β- and γ-secretases is a pivotal event i...
The membrane-embedded γ-secretase complex carries out hydrolysis within the lipid bilayer in proteol...
γ-secretase is responsible for the proteolysis of amyloid precursor protein (APP) into short, aggreg...
Background: Aβ peptides are generated by stepwise cleavage of the amyloid precursor protein. Results...
BACE1 (β-secretase) and α-secretase cleave the Alzheimer's amyloid β protein (Aβ) precursor (APP) to...
ABSTRACT: γ-Secretase catalyzes the final cleavage of the amyloid precursor protein (APP), resulting...
SummaryDevelopment of disease-modifying therapeutics is urgently needed for treating Alzheimer disea...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
Alzheimer Disease (AD) is the most common neurodegenerative disorder in the world. One of the neurop...
γ-secretase is involved in the final processing of the amyloid precursor protein into a heterogeneou...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...